Primaxin (cilastatin/imipenem)
/ Abbott
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
429
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
July 14, 2025
Combined Percutaneous Sclerotherapy Plus Transarterial Embolization for Refractory Sports Injuries in Young Athletes: A Feasibility Study.
(PubMed, Cardiovasc Intervent Radiol)
- "The combined sclerotherapy plus embolization technique is feasible and safe for treating refractory lower-extremity tendinopathies in young athletes. Comparative studies are needed to assess potential added benefits."
Journal • Pain
July 01, 2025
PIVOT-PO: A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
(clinicaltrials.gov)
- P3 | N=1690 | Completed | Sponsor: Spero Therapeutics | Recruiting ➔ Completed | N=2648 ➔ 1690 | Trial completion date: Nov 2025 ➔ Feb 2025 | Trial primary completion date: Nov 2025 ➔ Jan 2025
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology
June 22, 2025
Successful management of Nocardia farcinica brain abscess in an immunocompetent adult with trimethoprim/sulfamethoxazole hypersensitivity: A case report and review.
(PubMed, Diagn Microbiol Infect Dis)
- "N. farcinica brain abscess can occur in immunocompetent adults, posing therapeutic challenges with TMP/SMX intolerance. This case demonstrates that alternative regimens-imipenem/cilastatin, amikacin, amoxicillin, and minocycline-can achieve sustained remission. Individualized therapy based on drug susceptibility and patient factors is critical."
Journal • CNS Disorders • Epilepsy • Immunology • Infectious Disease
June 22, 2025
Impact of Antibiotic Post-Prescription Authorization in Resource-Limited Emergency Rooms and Acute Care Units
(ASM Microbe 2025)
- "In August 2020, a PPA was implemented for piperacillin/tazobactam, meropenem, imipenem/cilastatin and ertapenem. This study demonstrates the positive impact of PPA on antibiotic consumption and clinical outcomes in emergency settings. Future studies should evaluate PPA early in the course of treatment to identify the most effective interventions for improving the quality of care."
Infectious Disease
June 22, 2025
Impact of Antimicrobial Stewardship Program Suspension on Antibiotic Use during a Healthcare System Crisis: A Single-Center Experience in South Korea
(ASM Microbe 2025)
- "Preauthorization antibiotics included carbapenems (meropenem, imipenem/cilastatin, and ertapenem), ceftazidime/avibactam, and ceftolozane/tazobactam. PAF antibiotics included colistin, daptomycin, glycopeptides (vancomycin and teicoplanin), linezolid, and tigecycline... The suspension of antimicrobial stewardship interventions resulted in a significant increase in the use of restricted antibiotics, particularly those requiring preauthorization, highlighting the essential role of ASP in controlling antibiotic overuse and misuse."
Clinical
June 16, 2025
A case report of peritoneal dialysis-associated peritonitis caused by Mycobacterium mageritense.
(PubMed, IJID Reg)
- "Based on susceptibility testing, treatment was initiated with trimethoprim/sulfamethoxazole (TMP/SMX) (80 mg/400 mg) 5 mg/kg every 24 hours in combination with minocycline 100 mg every 12 hours, which was subsequently changed to TMP/SMX plus faropenem 200 mg every 8 hours due to nausea caused by minocycline...We switched to TMP/SMX, imipenem/cilastatin 500 mg every 12 hours, and used linezolid 600 mg every 12 hours, which was later replaced with amikacin, guided by therapeutic drug monitoring...We treated the patient with TMP/SMX and sitafloxacin 100 mg every 24 hours, which was well-tolerated...Our findings underscore the importance of suspecting non-tuberculous mycobacteria in PD catheter-related infection and considering the early inclusion of acid-fast bacillus culture. Given the diagnostic challenges and the complexity of managing multi-drug antimicrobial therapy in patients with renal dysfunction, we recommend early catheter removal."
Journal • Chronic Kidney Disease • Diabetic Nephropathy • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Renal Disease • Respiratory Diseases
June 16, 2025
Wound dehiscence rates decreased in reconstructive surgery of anorectal malformations after introduction of a standardized postoperative treatment program.
(PubMed, World J Pediatr Surg)
- "The standardized post-PSARP program comprised a minimum of 3 days of: intravenous antibiotics imipenem+cilastatin (with optional subsequent oral amoxicillin+clavulanic acid+metronidazole), fasting after primary PSARP (no stoma), urinary catheter and regular wound cleansing...In primary PSARPs (no stoma, 59% males), wound dehiscence developed in 6 of 33 patients (18%) in the standardized post-PSARP program group versus 17 of 40 patients (43%) in the control group (p=0.026). Wound dehiscence rates may be reduced using a standardized post-PSARP treatment program."
Journal • Pediatrics
May 29, 2025
TARGETING PAIN IN THE FIRST METATARSOPHALANGEAL JOINT: A NEW COMPLEMENTARY APPROACH IN RHEUMATOLOGY AND INTERVENTIONAL RADIOLOGY COLLABORATION USING EMBOLIZATION
(EULAR 2025)
- "Imipenem/cilastatin-based embolization offers a minimally invasive, effective alternative for managing refractory MTPJ pain of various etiologies. The technique demonstrates significant improvements in pain relief and functional outcomes, with a favorable safety profile compared to surgical interventions. Future studies involving larger cohorts, multi-center settings, and long-term follow-up are needed to validate its safety, efficacy, and sustained clinical benefits."
Anesthesia • Ankylosing Spondylitis • Gout • Immunology • Inflammation • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis
March 30, 2025
A new treatment alternative for patients with painful hand osteoarthritis: Early results of the efficacy and safety of intraarterial imipenem-silastatin therapy
(EULAR 2025)
- "All patients (100%) had previously used NSAIDs, seven patients (77.8%) had low-dose glucocorticoids, five patients (55.6%) had colchicine, four patients (44.4%) had hydroxychloroquine and two patients (22.2%) had a history of biologic disease-modifying anti-rheumatic drug (DMARD) use due to misdiagnosis. In clinical practice, treatment options for patients with painful hand OA are very limited. A study by Kubo T et al. from Japan demonstrated the efficacy and safety of intra-arterial imipenem-cilastatin+iodinated contrast embolisation in 92 patients with hand OA in 2023 [1]."
Clinical • Dermatology • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Urticaria
June 10, 2025
A case of portal venous gas caused by the use of a nasojejunal nutrition tube.
(PubMed, J Int Med Res)
- "This patient was discharged after 1 week of treatment with imipenem/cilastatin sodium for anti-infection, gastrointestinal decompression, fluid replacement, and pain relief, and the patient's abdominal pain was significantly relieved...The successful treatment of this patient highlights that addressing physical factors, providing gastrointestinal decompression, and administering anti-infection therapy can aid in the management of such cases. Bacterial culture of gastric juice and drug sensitivity testing can guide effective anti-infection treatment."
Journal • Infectious Disease • Nephrology • Pain • Pulmonary Disease • Respiratory Diseases
June 06, 2025
Clinical study of polymyxin E sodium mesylate in the treatment of carbapenem-resistant gram-negative bacteria (CRO) infection in critically ill patients
(ChiCTR)
- P4 | N=40 | Recruiting | Sponsor: Hangzhou Linping Hospital of Traditional Chinese Medicine; Hangzhou Linping Hospital of Traditional Chinese Medicine
New P4 trial • Infectious Disease
June 06, 2025
Clinical Outcomes of Shoulder Artery Embolization for Adhesive Capsulitis.
(PubMed, Cardiovasc Intervent Radiol)
- "TAE achieved pain reduction and functional improvement in patients with adhesive capsulitis refractory to conservative treatments."
Clinical data • Journal • Pain
June 05, 2025
Disseminated Nontuberculous Mycobacterial Infection Following Cerebral Shunt Infection Caused by Mycobacterium fortuitum: A Case Report and Literature Review.
(PubMed, Intern Med)
- "We diagnosed the patient with disseminated nontuberculous mycobacterial infection due to M. fortuitum and removed the ventriculoatrial shunt. Multiple antimicrobial agents (imipenem/cilastatin, linezolid, ciprofloxacin, and trimethoprim/sulfamethoxazole) were administered for approximately two months, and the symptoms improved."
Journal • CNS Disorders • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases • Ventriculomegaly
May 14, 2025
A rare case of multiple brain abscesses caused by Nocardia abscessus co-infection with tuberculous meningitis in an immunocompetent patient.
(PubMed, BMC Infect Dis)
- "Nocardial brain abscesses are associated with a high mortality rate, especially among immunocompromised patients and those with multiple abscesses. Prompt diagnosis, aggressive surgical intervention, and sensitive antibiotic treatment offer the best prospects for curing nocardiosis. Tuberculous meningitis, the most lethal manifestation of Mycobacterium tuberculosis infection, often leads to severe outcomes primarily due to delayed diagnosis and treatment. The GeneXpert/RIF assay, an emerging diagnostic tool, provides a more sensitive and rapid means of detecting TBM. For patients with a high clinical suspicion of TBM, empirical anti-tuberculosis treatment should be initiated immediately. Timely and accurate management, coupled with continuous monitoring of the patient's condition, is crucial for achieving a favorable prognosis."
Journal • CNS Disorders • Infectious Disease • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock • Tuberculosis • Ventriculomegaly
May 01, 2025
Application of metagenomic next-generation sequencing in the diagnosis and treatment of acute pneumonia caused by Tropheryma whipplei.
(PubMed, BMC Pulm Med)
- "The mNGS examination of bronchoalveolar lavage fluid can significantly improve the early diagnosis of acute pneumonia caused by Tropheryma whipplei. The treatment involving imipenem-cilastatin combined with SMZ-TMP, followed by oral SMZ-TMP for three months, is effective."
Biomarker • Journal • Next-generation sequencing • Infectious Disease • Pneumonia • Respiratory Diseases
April 27, 2025
Antibacterial efficacy of cefoperazone/sulbactam in combination with various antimicrobials against carbapenem-resistant Klebsiella pneumoniae.
(PubMed, Acta Microbiol Immunol Hung)
- "However, the current therapy for CRKP infection is polymyxin and tigecycline. The aim of this study is to analyze the in vitro antibacterial effects of cefoperazone/sulbactam (SCF) combined with ceftazidime (CAZ), imipenem/cilastatin (IMI), and meropenem (MEM) against CRKP harbouring different antibiotic resistance genes...The results of time-kill curve showed that SCF combined with IMI had good antibacterial effect. This study found that SCF combined with IMI has a synergistic antibacterial effect on KPC producing carbapenem-resistant K. pneumoniae, which could provide reference for clinical practice."
Journal • CNS Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock
April 17, 2025
Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: a randomized controlled trial.
(PubMed, J Infect)
- "Among critically ill patients meeting the sepsis-3 definition, this study could not demonstrate superiority of continuous infusion of beta-lactam antibiotics compared to intermittent bolus in achieving clinical cure."
Journal • Critical care • Human Immunodeficiency Virus • Infectious Disease • Septic Shock
April 15, 2025
Case Report: Nanopore Sequencing-Based Detection of Pulmonary Nocardiosis Caused by Nocardia Otitidiscaviarum in an Immunocompetent Patient.
(PubMed, Infect Drug Resist)
- "The patient's symptoms and signs showed improvement following treatment with imipenem cilastatin, linezolid and SMZ/TMP. This case presents a pulmonary infection caused by N. otitidiscaviarum in an immunocompetent patient, where the pathogen was identified within 4 hours through NS. This rapid and accurate diagnostic approach offers significant advantages for the timely diagnosis of pulmonary nocardiosis."
Journal • Infectious Disease • Respiratory Diseases
January 28, 2025
CUPPING THERAPY GONE AWRY: A CASE OF ACINETOBACTER ENDOCARDITIS AND PULMONARY SEPTIC EMBOLI IN A HEALTHY YOUNG ADULT - Mohanad Qwaider
(ACC 2025)
- "Empirical treatment with vancomycin and gentamicin was initiated. Blood cultures revealed the growth of Acinetobacter species.Decision-making: Based on blood culture susceptibility results, the regimen was modified to imipenem-cilastatin and trimethoprim-sulfamethoxazole for a total of 6 weeks, resulting in a significant clinical response... Although it is rare, Acinetobacter can cause IE of a native valve even in healthy individuals. Detailed patient history and appropriate diagnostic testing are crucial."
Clinical • Cardiovascular • Heart Failure • Infectious Disease • Pneumonia • Pulmonary Embolism • Respiratory Diseases
April 03, 2025
Aeromonas veronii-induced septic arthritis of the hip in a child with acute lymphoblastic leukemia.
(PubMed, Open Life Sci)
- "The child's condition was successfully treated with a combination of amikacin and imipenem-cilastatin, leading to improvement and subsequent discharge in a satisfactory state. SAH caused by A. veronii is a rare occurrence, and the utilization of mNGS holds significant potential for the early detection of uncommon infections in immunosuppressed children."
Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pain • Rheumatology
March 05, 2025
HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study
(ESCMID Global 2025)
- No abstract available
Clinical • Late-breaking abstract • P2 data • Infectious Disease • Nephrology
February 04, 2025
Are meropenem or imipenem-cilastatin effective therapies for patients with invasive ertapenem-resistant infections?
(ESCMID Global 2025)
- No abstract available
Clinical • Infectious Disease
March 25, 2025
Transcatheter Arterial Embolization as a Treatment for Chronic Pain due to Osteoarthritis.
(PubMed, Cardiovasc Intervent Radiol)
- "TAE appears to be a feasible and safe minimally-invasive option for selected TMJ-OA patients with symptoms refractory to standard treatments. Further studies with larger cohorts and extended follow-up are warranted to confirm these preliminary findings."
Journal • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology
March 25, 2025
Ultrasound-guided thoracentesis for diagnosing Nocardia beijingensis-related empyema in a patient with systemic lupus erythematosus: A rare case report.
(PubMed, Radiol Case Rep)
- "We present a case of a 49-year-old female patient with SLE on immunosuppressive therapy (corticosteroids and azathioprine), admitted with dyspnea and left-sided pleuritic chest pain...The patient received empirical intravenous antibiotic therapy with imipenem/cilastatin and vancomycin without isolating the causative organism for 10 days...Ultrasound-guided aspiration, targeting the loculated and encapsulated effusion, played a crucial role in confirming the diagnosis. Empirical treatment with imipenem/cilastatin combined with long-term oral trimethoprim/sulfamethoxazole was found to be effective."
Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Pain • Pulmonary Disease • Respiratory Diseases • Systemic Lupus Erythematosus
March 14, 2025
Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?
(PubMed, Antimicrob Agents Chemother)
- "Sulbactam-durlobactam was combined with imipenem-cilastatin in a clinical trial that led to its United States Food and Drug Administration approval. However, the additive benefit of imipenem remains uncertain. In a recent study (Antimicrob Agents Chemother 69:e01627-24, 2025, https://doi.org/10.1128/aac.01627-24), Veeraraghavan and colleagues provide convincing mechanistic evidence that adding imipenem to sulbactam-durlobactam enhances bacterial killing, likely through complementary inhibition of penicillin binding proteins, leveraging the concept of target redundancy."
Journal • Infectious Disease
1 to 25
Of
429
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18